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Several studies suggest that the peptide hormone ghrelin mediates some of the usual behavioral responses to acute and chronic
stress. Circulating ghrelin levels have been found to rise following stress. It has been proposed that this elevated ghrelin helps
animals cope with stress by generating antidepressant-like behavioral adaptations, although another study suggests that decreasing
CNS ghrelin expression has antidepressant-like eﬀects. Ghrelin also seems to have eﬀects on anxiety, although these have been
shown to be alternatively anxiogenic or anxiolytic. The current review discusses our current understanding of ghrelin’s roles in
stress, mood, and anxiety.
1.Introduction
Metabolic syndrome and psychiatric disorders have become
leading threats to the public health worldwide, and associ-
ations between the two now have been reported in several
studies. For instance, a growing body of literature indicates
that obesity is an important environmental risk factor for
developing aﬀective disorders. As an example, in a large
crosssectionalepidemiological U.S.study,a body massindex
≥30 was found to be associated with a 25% higher rate
of mood disorders [1, 2]. Conversely, other studies suggest
that psychological stress can increase the risk of developing
obesity. For instance, a longitudinal study found that major
depression in late adolescent girls was associated with a
2.3-fold increased risk of obesity in adulthood [3]. Also,
a chart review of U.S. veterans with posttraumatic stress
disorder showed a signiﬁcantly increased rate of obesity
[4]. Thus, it seems likely that certain circulating hormones
and critical neuroanatomical circuits exist that regulate both
energy homeostasis and our psychological state. Work from
a handful of laboratories now suggests that the peptide
hormone ghrelin is one such mediator of both behaviors
linked to food intake and body weight and behaviors
associated with psychosocial stress, mood, and anxiety.
2.ChangesinGhrelinAssociatedwith
PsychosocialStress
We and others have found that rises in ghrelin occur
not only in response to states of energy insuﬃciency [5–
8] but also following stress [9]( Figure 1). For example,
elevations in either gastric ghrelin mRNA or total plasma
g h r e l i nh a v eb e e no b s e r v e di nr e s p o n s et ov a r i o u sm o d e l s
of acute stress, including following a tail pinch stress
protocol in ddy mice and following a water avoidance
stress protocol in Wistar Kyoto and Sprague-Dawley rat
[10, 11]. Also, rises in desacyl and acylated ghrelin plasma
levels, preproghrelin mRNA levels, and numbers of ghrelin
cells were shown in Wistar rats following 5 days con-
tinuous exposure to 2cm of water [12]. Our own study
found that acylated ghrelin levels rise in C57BL6/J mice in
response to chronic social defeat stress (CSDS); in particular,
ghrelin was signiﬁcantly elevated on the day following
the 10-day CSDS protocol and remained elevated when
assessed again one month later [9]. In addition, human
subjects subjected acutely to psychosocial stress also display
increased plasma ghrelin [13]. Supportively, epinephrine,
which increases with stress, can increase circulating ghrelin








Figure 1: Two opposing models for ghrelin action in the behavioral
responses to stress. Published studies all seem to agree that ghrelin
levels rise upon stress of various types. Some studies suggest that
rising ghrelin would contribute to the mechanisms responsible for
the development of stress-induced depression and anxiety (upper
panel), while others suggest that rising ghrelin helps minimize what
otherwise would be more severe manifestations of depression and
anxiety following stress (lower panel).
3.Ghrelin’sRoleinMood
The eﬀects of these stress-induced increases in ghrelin likely
include eﬀects on metabolism-related physiology and behav-
i o ra sw e l la se ﬀects on mood. Our own work using mouse
models has revealed that increasing circulating ghrelin levels
by 10 days of calorie restriction or by acute s.c. injection
produces antidepressant-like responses in the forced swim
test [9]. However, caloric restriction no longer induced
these responses in mice lacking ghrelin receptors (GHSR-
null mice), thus suggesting that interference with ghrelin sig-
naling negates the antidepressant-like behaviors associated
with calorie restriction [9]. Also, upon challenge with the
CSDS protocol, GHSR-null mice manifested greater social
isolation (another marker of depressive-like behavior) than
did wild-type littermates [9]. Thus, it has been suggested
that activation of ghrelin signaling pathways in response to
chronic stress may be a homeostatic adaptation that helps
individuals cope with stress (Figure 1, lower panel).
We are aware of only one other study that examines
the eﬀects on mood of manipulations to ghrelin expression
[15]. For this latter trial, behaviors were examined in
rats subsequent to i.c.v. administration of antisense ghrelin
oligonucleotides. Rats receiving the antisense ghrelin DNA
exhibited much less immobility in the forced swim test
as compared to rats receiving scrambled oligonucleotides,
thussuggestinganantidepressant-likeeﬀect[15].Associative
studies that examine a ghrelin-mood relationship also exist,
including one in which a GHSR polymorphism was found
associated with major depressive disorder [16] and another
in which total plasma ghrelin levels were compared among
subjects with major depression, schizophrenia, and controls
[17].
It is also important to note that ghrelin now has been
shown in a handful of studies to aﬀect reward behavior
of various types. For example, ghrelin lowers the threshold
dose of cocaine required to establish a conditioned place
preference, is required for alcohol reward, and itself can
elicit a conditioned place preference [18–20]. Ghrelin also
increasesneuronalactivityinbrainrewardcentersinhumans
shown images of appealing foods [21] and has been shown
to enhance the rewarding value of high-fat diet when
administered to ad lib-fed mice [22]. These ﬁndings are
relevant to the discussion of mood as anhedonia is a major
component of most forms of depression and as reward
behaviors and mood-related behaviors share many of the
same neural circuits (see below) [23].
4.Ghrelin’sRole inAnxiety
Several groups have investigated ghrelin’s eﬀects on anxiety-
like behaviors. Using models identical to those described
above, we showed that increasing circulating ghrelin levels
by calorie restricting mice for ten days or by acute s.c.
administration of ghrelin to ad lib-fed C57BL6/J mice
produces anxiolytic-like responses in the elevated plus maze
[9]. However, when GHSR-null mice were calorie restricted,
no longer were these anxiolytic-like behavioral responses
observed [9]. Thus, we proposed that ghrelin has anxiolytic-
like eﬀects and that ghrelin signaling is required for the
anxiolytic-like eﬀects of caloric restriction [9]. Our observa-
tions seem to be supported by a report showing that Wistar
Kyoto rats, which are thought to display more anxiety-
like behaviors than Sprague-Dawley and other rat strains,
have lower plasma levels of ghrelin than Sprague-Dawley
rats [24]. Furthermore, although stress-induced elevations
in circulating ghrelin have been noted in both Wistar Kyoto
and Sprague-Dawley rat strains, the magnitude of those
elevationswassigniﬁcantlylowerintheanxiety-proneWistar
Kyoto animals than in the Sprague-Dawley animals [11].
These ﬁndings of anxiolytic-like eﬀects of raised ghrelin
levels diﬀer from the results of several other studies. In one
of these studies, i.c.v. or i.p. administration of ghrelin to ddy
mice decreased duration of time in and number of entries
into the open arms of an elevated plus maze (anxiogenic-
like actions) when assessed ten minutes after injection [10].
Another group demonstrated that i.c.v. administration of
ghrelin or its direct microinjection into the hippocampus,
amygdale, or dorsal raphe nucleus induced anxiety-like
behaviors in certain rat strains when assessed 5 minutes
later in the elevated plus maze, open ﬁeld test and step-
down/inhibitory avoidance test [25, 26]. Also, i.c.v. admin-
istration of antisense ghrelin oligonucleotides induced not
only antidepressant-like behaviors but also anxiolytic-like
responses in rats [15]. Finally, a recent study demonstrated
that i.c.v. administration of ghrelin to chicks can induce
anxiogenesis [27].
The reasons for the varied anxiety-related behavioral
responses to changes in ghrelin signaling are not clear,
at present (Figure 1, upper versus lower panels). They
could potentially be due to diﬀerences in dose, route of
administration, timing of administration, timing of behav-
ioral test after administration, strain or species, or other
experimental details such as handling of animals. Strain-
dependent diﬀerences in performance in various behavioral
tasks, such as the elevated plus maze and forced swim testInternational Journal of Peptides 3
are not uncommon (as an example, in one study, only one
out of four inbred strains of mice exhibited sensitivity to
ﬂuoxetine in the forced swim test [28]). Further studies will
be required to sort out how these discrepant anxiety-related




The mechanisms by which ghrelin aﬀects mood-related
behaviors have not yet been fully elucidated, but likely
include interaction with its receptors in one or more
brain sites critical to mood determination. We have shown
that ghrelin’s ability to decrease immobility in the forced
swim test is dependent on the presence of orexin [9], and
previous work has demonstrated that the antidepressant-
like responses to calorie restriction (which also causes an
increase in ghrelin) requires orexin [29]. Both direct and
indirect links between ghrelin and orexin exist. The most
direct link would involve binding of ghrelin to GHSRs
present on orexin neurons. Such would be supported by
previous studies demonstrating GHSRs within the lateral
hypothalamic area of rat, where orexin-containing neuronal
cell bodies exist [30], as well as those showing that ghrelin
can induce action potentials in isolated orexin neurons [31].
Alternatively, ghrelin might indirectly engage the orexin
systembytargetingneuronsatotherlocationswhich,inturn,
project to the lateral hypothalamic area. For instance, several
studies suggest that ghrelin directly engages its receptors on
AgRP/NPY neurons of the hypothalamic arcuate nucleus (as
reviewed in [32, 33]), which are also known to project to
lateral hypothalamic orexin neurons [34].
Ghrelin’s actions on mood also might involve direct
interaction with GHSR-containing neurons that exist within
the ventral tegmental area. There is growing evidence for a
role of the ventral tegmental area (VTA) and its dopaminer-
gicprojectionstothenucleusaccumbensinmoodregulation
and depression [23]. These circuits, in addition to related
projectionsfromtheVTAtotheamygdalaandlimbicregions
of neocortex, are particularly involved in motivation, the
valuation of rewards, the establishment of reward-associated
memories and the ability to experience pleasure; impairment
of all of these features prominently in the manifestation of
depression [35, 36]. As just one example of VTA involvement
in depression, chronic social defeat stress has been shown to
be associated with a signiﬁcant increase in VTA dopamine
neuron ﬁring rates [37]. In fact, ghrelin also increases action
potential frequency in ventral tegmental area neurons and
induces dopamine release into the nucleus accumbens [38–
40]. Furthermore, ventral tegmental area microinjection of
ghrelinincreasesfoodintakewhilemicroinjectionofaGHSR
antagonist into the VTA decreases food intake in response to
i.p.-injected ghrelin [38, 41].
A large body of work has identiﬁed the hippocampus as
being involved in antidepressant eﬃcacy and other aspects
of depression, including that associated with stress [42].
Many studies have shown that the hippocampus together
with the neocortex mediates cognitive aspects of depression
such as memory impairment and feelings of worthlessness,
hopelessness, guilt, and suicidality [42]. Also, antidepressant
therapy stimulates hippocampal neurogenesis, in a time
course that seems consistent with the delayed onset of
therapeutic action of antidepressant agents [43]. Of interest,
GHSRs are known to be expressed within all regions of
the hippocampus [30, 44, 45]. In addition, peripherally
administered ghrelin is taken up by and increases spine
synapse density within the hippocampus [46]. Ghrelin-
deﬁcient mice perform poorly in tests of behavioral memory,
while ghrelin administration reverses these deﬁcits [46].
Direct microinjection of ghrelin into the hippocampus dose-
dependently increases memory retention [26]. Ghrelin also
recently has been shown to stimulate cellular proliferation
and diﬀerentiation of adult rat hippocampal progenitor cells
[47, 48], thus suggesting that ghrelin also might induce
hippocampal neurogenesis.
Finally, ghrelin’s action on mood may be mediated
through the modulation of brain inﬂammation. Mounting
evidence indicates that inﬂammation may play a role in
psychiatric diseases (as reviewed in [49, 50]). For example,
correlative studies have suggested the association between
inﬂammation markers and depressive symptoms [51]. In
addition, several studies have shown that administration
of cytokine or cytokine inducers such as LPS or vaccine
can lead to the development of depressive symptoms,
while antiinﬂammatory therapy generates antidepressant-
like eﬀects [52–54]. GHSRs have been found to be expressed
in immunocytes [55] and ghrelin or ghrelin mimetics also
have been shown to have immunosuppressive actions via
the inhibition of proinﬂammatory cytokines such as IL1-
beta, IL-6, and TNF-alpha [56–59]. Together, these data
suggestthatthestress-inducedelevationsinghrelinmayhelp
to alleviate the potential damage that could be caused by
inﬂammation within the brain.
6. Summary
Several groups have now demonstrated that rises in ghrelin
occurnotonlyduringperiodsofenergyinsuﬃciencybutalso
following either acute or chronic stress. Investigations into
the ramiﬁcations of these stress-associated ghrelin increases
are only in their early stages. Our own work suggests
that these raised ghrelin levels may help to minimize the
deleterious, depression-like behaviors often associated with
stress, but perhaps at the expense of a worsened metabolic
proﬁle. Future studies are needed to sort out ghrelin’s
eﬀects on anxiety-like behaviors, as these have been shown
by diﬀerent groups to be either anxiogenic or anxiolytic.
Certainly, it is crucial that these diﬀerences in the proposed
action of ghrelin on anxiety-like behaviors be resolved given
the impact that they might have on the side-eﬀect proﬁle
of any GHSR antagonist in development as an antiobesity
or antidiabetes agent. Also, the antidepressant-like actions
and possible anxiolytic-like actions of ghrelin potentially
might enhance the eﬀectiveness of ghrelin mimetics being
consideredforthetreatmentofcachexiaoranorexianervosa.4 International Journal of Peptides
Future studies should also be directed towards determining
the mechanisms by which ghrelin acts to have its eﬀects
on mood-related and anxiety-related behaviors as well as
the pathways responsible for the stress-induced elevations in
ghrelin.
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